Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

ESTERO, FL / ACCESS Newswire / December 12, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, received notice (the "Notice") on December 11, 2025, from the Nasdaq Listing Qualifications Panel (the "Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") that the Hearings Panel has granted the Company's request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain conditions upon transfer of its common stock to The Nasdaq Capital Market, including demonstrating compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule") on or before January 30, 2026 and with Listing Rule 5550(b)(1) (the "Equity Rule") on or before February 17, 2026.

In connection with the Notice, the Company will transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market effective as of the opening of business on December 15, 2025. The Company's common stock will continue to be traded under the symbol "ASBP" and trading of its common stock will be unaffected by this transfer.

"We believe the extension granted by the Nasdaq Hearings Panel will allow us to finish executing on our plan to regain compliance with Nasdaq's requirements," said Kraig Higginson, Interim CEO of Aspire. "We expect the Company will cure the bid price and market value of listed shares deficiencies within the required time frame. We are undertaking substantial steps in an effort to recapitalize the balance sheet and set up the Company to deliver long term value to our shareholders."

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma's delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.